“With this award, we honor a true pioneer in Alzheimer’s research,” said Professor Gabor Petzold, acting Chairman of DZNE. “Lecanemab has opened new avenues in treatment. The drug targets a central mechanism of Alzheimer’s disease and can slow down its progression when administered at an early stage. This is a major advance – because conventional therapies can only alleviate symptoms, but do not address the root causes of Alzheimer’s. Lars Lannfelt paved the way for this development.” “We award.